Episode Details
Back to Episodes
Mar 2, 2026 | Gilead’s $7.8B CAR-T Bet, YUVIWEL Approved, PADCEV-Keytruda Resets Bladder Cancer
Published 4 months, 3 weeks ago
Description
Gilead acquires Arcellx for $7.8B to challenge J&J’s Carvykti in multiple myeloma with a December FDAdecision approaching. Both Friday decisions resolved: YUVIWEL wins accelerated approval as the first weekly achondroplasia treatment, Dupixent adds AFRS toits ENT franchise. PADCEV plus Keytruda delivers a 47% recurrence reduction in muscle-invasive bladder cancer. CagriSema analyst downgrades continue, and theMarch 20th Rhythm decision could reshape the obesity landscape.